Why the study?
Multiple biomarkers beyond natriuretic peptides have been included in recent HF management guidelines, prompting a review of their roles and future perspectives.
Natriuretic peptides remain the cornerstone biomarkers in heart failure guidelines, whereas novel biomarkers require further validation before widespread clinical adoption.
Natriuretic peptides aid HF diagnosis, prognosis, and monitoring; leaves open incremental value of novel biomarkers in routine care.
Heart failure (HF) is a common cardiovascular disease that has a complex pathophysiology. Because it is the final stage of many cardiovascular diseases, proper diagnosis and treatment are crucial for prolonging patients’ survival and improving their well-being. Several biomarkers have been identified in HF, and their roles in diagnosis and prognostication have been widely investigated. Among them, natriuretic peptides are key for diagnosing HF, predicting its prognosis, and monitoring the effectiveness of HF treatment. Moreover, natriuretic peptides can also be used to treat HF. In addition to natriuretic peptides, several other biomarkers were included in the most recent HF management guidelines. Thus, we reviewed the role of the biomarkers included in these guidelines and discussed future perspectives.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: